Literature DB >> 25015396

Thyroid carcinoma after treatment for malignancies in childhood and adolescence: from diagnosis through follow-up.

Marta Giorgia Podda1, Monica Terenziani, Lorenza Gandola, Paola Collini, Natalia Pizzi, Alfonso Marchianò, Carlo Morosi, Roberto Luksch, Andrea Ferrari, Michela Casanova, Filippo Spreafico, Daniela Polastri, Cristina Meazza, Serena Catania, Elisabetta Schiavello, Veronica Biassoni, Maura Massimino.   

Abstract

With improvements in the survival rates after childhood cancer, many clinicians have turned their attention to reporting on late effects, and how they might be prevented or treated. In childhood the thyroid gland is especially vulnerable to the carcinogenic action of ionizing radiation. This retrospective study focused on secondary thyroid cancers seen at our institution over more than 30 years (between 1980 and 2012) in patients treated for other malignancies in pediatric age. 36 patients were identified. In most cases, the primary cancer had been Hodgkin disease, and all the patients had been administered radiotherapy for their first malignancy. The secondary thyroid cancers were treated with total thyroidectomy in 27 cases (six with lymphadenectomy), and hemithyroidectomy in nine (one with lymphadenectomy). 12 Patients were also given radiometabolic therapy. All but two had TSH suppression therapy. The histological diagnoses were: 31 papillary and five follicular carcinomas. At 5 and 10 years, the OS was 100 and 95 %, respectively, and the PFS was 96 and 83 %. None of the patients died of their thyroid disease. Nodal involvement at onset was the only factor correlating with recurrence. Surgical sequelae only occurred in patients who underwent total thyroidectomy. Survival in these patients did not depend on the extent of surgery on the thyroid parenchyma. Our data confirm a good prognosis for secondary thyroid cancer, prompting us to encourage a minimalist approach to the treatment of these particular patients wherever possible.

Entities:  

Mesh:

Year:  2014        PMID: 25015396     DOI: 10.1007/s12032-014-0121-6

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  26 in total

1.  Thyroid disease 60 years after Hiroshima and 20 years after Chernobyl.

Authors:  John D Boice
Journal:  JAMA       Date:  2006-03-01       Impact factor: 56.272

2.  Long-term impact of initial surgical and medical therapy on young patients with papillary thyroid cancer and bilateral cervical metastases.

Authors:  Qing-hai Ji; Ling Zhang; Yong-xue Zhu; Cai-ping Huang
Journal:  Chin Med J (Engl)       Date:  2008-01-05       Impact factor: 2.628

3.  Differentiated thyroid cancer: determinants of disease progression in patients <21 years of age at diagnosis: a report from the Surgical Discipline Committee of the Children's Cancer Group.

Authors:  K D Newman; T Black; G Heller; R G Azizkhan; G W Holcomb; C Sklar; V Vlamis; G M Haase; M P La Quaglia
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

4.  Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the childhood cancer survivor study.

Authors:  Gregory T Armstrong; Wei Liu; Wendy Leisenring; Yutaka Yasui; Sue Hammond; Smita Bhatia; Joseph P Neglia; Marilyn Stovall; Deokumar Srivastava; Leslie L Robison
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

5.  Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study.

Authors:  Parveen Bhatti; Lene H S Veiga; Cécile M Ronckers; Alice J Sigurdson; Marilyn Stovall; Susan A Smith; Rita Weathers; Wendy Leisenring; Ann C Mertens; Sue Hammond; Debra L Friedman; Joseph P Neglia; Anna T Meadows; Sarah S Donaldson; Charles A Sklar; Leslie L Robison; Peter D Inskip
Journal:  Radiat Res       Date:  2010-10-06       Impact factor: 2.841

6.  Thyroid surgery at Children's Hospital Boston: a 35-year single-institution experience.

Authors:  Stefan Scholz; Jessica R Smith; Beverly Chaignaud; Robert C Shamberger; Stephen A Huang
Journal:  J Pediatr Surg       Date:  2011-03       Impact factor: 2.545

7.  Chemotherapy and thyroid cancer risk: a report from the childhood cancer survivor study.

Authors:  Lene H S Veiga; Parveen Bhatti; Cécile M Ronckers; Alice J Sigurdson; Marilyn Stovall; Susan A Smith; Rita Weathers; Wendy Leisenring; Ann C Mertens; Sue Hammond; Joseph P Neglia; Anna T Meadows; Sarah S Donaldson; Charles A Sklar; Debra L Friedman; Leslie L Robison; Peter D Inskip
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-10-25       Impact factor: 4.254

8.  Treatment strategy of papillary thyroid carcinoma in children and adolescents: clinical significance of the initial nodal manifestation.

Authors:  Nobuyuki Wada; Kiminori Sugino; Takashi Mimura; Mitsuji Nagahama; Wataru Kitagawa; Hiroshi Shibuya; Keiko Ohkuwa; Hirotaka Nakayama; Shohei Hirakawa; Norio Yukawa; Yasushi Rino; Munetaka Masuda; Koichi Ito
Journal:  Ann Surg Oncol       Date:  2009-09-24       Impact factor: 5.344

9.  Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group.

Authors:  M A Tucker; P H Jones; J D Boice; L L Robison; B J Stone; M Stovall; R D Jenkin; J H Lubin; E S Baum; S E Siegel
Journal:  Cancer Res       Date:  1991-06-01       Impact factor: 12.701

10.  Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study.

Authors:  J P Neglia; D L Friedman; Y Yasui; A C Mertens; S Hammond; M Stovall; S S Donaldson; A T Meadows; L L Robison
Journal:  J Natl Cancer Inst       Date:  2001-04-18       Impact factor: 11.816

View more
  1 in total

1.  Screening for thyroid cancer in survivors of childhood and young adult cancer treated with neck radiation.

Authors:  Emily S Tonorezos; Dana Barnea; Chaya S Moskowitz; Joanne F Chou; Charles A Sklar; Elena B Elkin; Richard J Wong; Duan Li; R Michael Tuttle; Deborah Korenstein; Suzanne L Wolden; Kevin C Oeffinger
Journal:  J Cancer Surviv       Date:  2016-12-27       Impact factor: 4.442

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.